SCHEMBL31509894

SCHEMBL31509894

O=C(O)C1[C@H]2C(=O)OC(=O)[C@@H]12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ GMNN O75496 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TFPI2 P48307 2/20 0.39
▸ PMP22 Q01453 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ NFKB1 P19838 2/20 0.39
▸ THPO P40225 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ PPM1B O75688 1/20 0.39
▸ PPP1CC P36873 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ PPP5C P53041 1/20 0.39
▸ PPP1CA P62136 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ TSHR P16473 2/20 0.35
▸ EDNRB P24530 2/20 0.34
▸ EDNRA P25101 2/20 0.34
▸ POLB P06746 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8918724 1.00 KDM4E (0.39) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL3137226 0.94 EDNRB (0.39) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL1436171 0.92 EDNRB (0.38) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL9994809 0.92 EDNRB (0.38) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL11262309 0.82 TDP1 (0.33) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL12834033 0.80 KDM4E (0.30) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL1672459 0.79 KDM4E (0.41) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL6321820 0.79 TDP1 (0.40) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL1150234 0.79 TDP1 (0.45) KDM4EGMNNLMNATFPI2PMP22
SCHEMBL14675352 0.77 LMNA (0.35) KDM4EGMNNLMNATFPI2PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127801-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-24 — — US disclosed
WO-2025080850-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127801-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF SDHA, SDHB, DPYD KDM4E 1168/4885GMNN 2473/4885LMNA 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback